Japan at a glance
- Population
- 123.4 million 2025
- Life expectancy at birth
- 84.0 years, 2024
- People aged 65 and over
- 30.0 % of people, 2025
- Health spending per person
- 3,638 US$ per person, 2023
- Doctors
- 2.65 per 1,000 people, 2022
Updated
Reviewed by Vidhi Upadhyay
Japan Benign Prostatic Hyperplasia Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$692.8 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $803.0 Mn | — | — |
| 2025 (base) | $857.6 Mn | +$54.6 Mn | — |
| 2026 (forecast) | $916.0 Mn | +$58.3 Mn | +6.8% |
| 2027 (forecast) | $978.2 Mn | +$62.3 Mn | +14.1% |
| 2028 (forecast) | $1.04 Bn | +$66.5 Mn | +21.8% |
| 2029 (forecast) | $1.12 Bn | +$71.0 Mn | +30.1% |
| 2030 (forecast) | $1.19 Bn | +$75.9 Mn | +38.9% |
| 2031 (forecast) | $1.27 Bn | +$81.0 Mn | +48.4% |
| 2032 (forecast) | $1.36 Bn | +$86.5 Mn | +58.5% |
| 2033 (forecast) | $1.45 Bn | +$92.4 Mn | +69.3% |
| 2034 (forecast) | $1.55 Bn | +$98.7 Mn | +80.8% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $857.6 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $1.55 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 6.8% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Treatment, setting and end user (see all) |
| Key players | Boston Scientific Corporation, Teleflex Inc, Olympus Corporation, Procept BioRobotics, Astellas Pharma Inc. (see all) |
| Regulator in Japan | PMDASource: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Benign prostatic hyperplasia treatments ease urinary problems from an enlarged prostate with medicines and minimally invasive procedures.
Key segments of the benign Prostatic Hyperplasia Treatment market include treatment (Alpha Blockers, 5-Alpha Reductase Inhibitors and Prostatic Urethral Lift) and setting (Hospitals, Urology Clinics and Ambulatory Surgery Centers).
An ageing male population, more men seeking care, less invasive procedures and telehealth for sensitive conditions are driving the benign Prostatic Hyperplasia Treatment market.
Office-based procedures, direct-to-consumer telehealth and wider insurance coverage give the benign Prostatic Hyperplasia Treatment market room to grow.
Stigma, out-of-pocket costs and limited reimbursement for some procedures hold back the benign Prostatic Hyperplasia Treatment market.
The benign Prostatic Hyperplasia Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medical devices are notified, certified or approved depending on their risk; the Pharmaceuticals and Medical Devices Agency (PMDA) reviews higher-risk devices for approval by the Ministry of Health, Labour and Welfare.[1] Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices).[2]
[1] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
[2] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how benign Prostatic Hyperplasia Treatment products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Japan.
What doctors and scientists are doing in Benign Prostatic Hyperplasia Treatment right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 17 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 18 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.
From our blog
Japan · 2 shared keywords
Japan · 2 shared keywords
Japan · 2 shared keywords
Japan · 1 shared keyword
Japan · 1 shared keyword
Japan · 1 shared keyword
Pharmaceuticals · Japan
Healthcare Services · Japan
Pharmaceuticals · Japan
Healthcare Services · Japan
Healthcare Services · Japan
Pharmaceuticals · Japan